
Please try another search
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds royalty interest in Takeda’s Obizur, which is a porcine recombinant Factor VIII for acquired Hemophilia A. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Name | Age | Since | Title |
---|---|---|---|
Rodney G. Hill | 56 | 2018 | Independent Director |
John Lee Welborn | 47 | 2021 | Independent Chairman of the Board |
Craig Stuart Millian | 56 | 2023 | CEO & Director |
Norma Beauchamp | 62 | 2021 | Independent Director |
Christian Roy | 60 | 2023 | Independent Director |
Kyle Dempsey | 36 | 2022 | Independent Director |
John Hanna | 59 | 2023 | CFO & Non-Independent Director |
Christine Elliott | 70 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review